Evidence map›Paper›PMID 39773043›Full record

ReviewCurrent medicinal chemistry2026

Interaction between microRNA and KRAS in Glioblastoma.

Ozal Beylerli, Elmar Musaev, Gervith Reyes Soto, Carlos Castillo Rangel, Manuel De Jesus Encarnacion Ramirez, Tatiana Ilyasova

Abstract readReview
In one paragraph

Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ozal BeylerliCentral Research Laboratory, Bashkir State Medical University, Ufa, Republic of Bashkortostan, 3 Lenin Street, 450008, Russia.
Elmar MusaevDepartment of Oncology, Sechenov First Moscow State Medical University, Moscow, Russia.
Gervith Reyes SotoDepartment of Head and Neck, Unidad de Neurociencias, Instituto Nacional de Cancerología, 14080, Mexico City, Mexico.
Carlos Castillo RangelDepartment of Neurosurgery, Servicio of the 1ro de Octubre Hospital of the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, 07760, Mexico.
Manuel De Jesus Encarnacion RamirezDepartment of Neurosurgery, Russian People's Friendship University, 121359, Moscow, Russia.
Tatiana IlyasovaDepartment of Internal Diseases, Bashkir State Medical University, Ufa, Republic of Bashkortostan, 450008, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) characterized byits rapid progression and challenging prognosis, often featuring mutations in the Kirsten rat sarcoma virus (KRAS) gene, which is crucial for numerous cellular signaling mechanisms. Emerging research underscores a significant interaction between KRAS and microRNAs (miRNAs) in these cancers, with miRNAs playing key roles as both regulators and mediators within the KRAS signaling framework. The concept of oncogene-induced senescence (OIS) is explored as a protective mechanism against tumor development, examining how K-RAS signaling is meticulously adjusted to bypass senescence, thereby enhancing cell growth and survival. In this study, we identify certain miRNAs that directly impact KRAS through mRNA targeting or by influencing its downstream signaling cascades. In turn, pathways activated by KRAS can modify the levels of specific miRNAs, establishing a feedback loop that balances cell regulation and tumor progression. We propose a theoretical framework where these interactions are crucial for deciphering the molecular underpinnings of GBM, potentially paving the way for innovative treatment approaches that focus on the miRNA-KRAS connection.

Indexed as

Brain NeoplasmsGlioblastomaMicroRNAsProto-Oncogene Proteins p21(ras)AnimalsGene Expression Regulation, NeoplasticHumansSignal TransductionKRAS protein, humanMicroRNAsProto-Oncogene Proteins p21(ras)GBMgliomagenesisKRAS genemiRNAtargetstherapy

Identifiers

PMID39773043
PMCPMC13555761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.